All participants provided written, informed consent before study entry and had the right to withdraw from the study at any time.
Patient: A 68-year-old woman who had a left anterior cerebral artery infarct 5 months before study entry and who exhibited learned nonuse of the affected upper limb.
Eligible subjects were children and adolescents (<17 years) who fulfilled the ICHD-II criteria for paediatric migraine with and/or without aura at the time of study, experienced migraine attacks for at least 6 months before study entry, and had had less than 15 headache days per month during last 3 months.
The inclusion criteria for the ESN was a history of multiple unprotected sexual episodes (with the same HIV-seropositive partner) for ≥4 years at the time of enrollment, with at least 8 episodes of at-risk intercourse within the 4 months before study entry, and an average of 30 reported unprotected sexual contacts per year (range 18 to >100).
Patients were reviewed in clinic before study entry and at 12 weeks as a minimum.
Weight and height were measured before study entry and after four months of intervention.
In the VADT, 324 participants had CAC and AAC before study entry and at study end.
Tumor assessment using computed tomography scans was carried out within 28 days before study entry and repeated every 4 weeks.
Bisphosphonates were not allowed before study entry, and only 7% of women ever used bisphosphonates in the LIBERATE trial.
Written informed consent was obtained before study entry and study procedures were in accordance with Helsinki Declaration.
Optional fresh frozen tumour tissue from an FDG PET targetable metastatic or primary lesion will be obtained before study entry and at disease progression.
